NunaBio, the synthetic DNA spin out from Newcastle University, has announced the appointment of Colin Mitchell as their new independent Board Chair.
Colin is a veterinary surgeon with 18 years’ experience as a business owner. He has also previously been appointed non-executive director and chair of financial committee for two other businesses. His qualifications and interests in finance, strategy and governance strongly support a Board-level position with NunaBio and it is with great pleasure that we welcome him to this.
CEO Joe Hedley says
“Colin has a wealth of experience in roles across business, finance and strategy, which brings an understanding and perspective that will be essential for the role. It is a fantastic appointment which confirms our ambition to take NunaBio to the next level.”
Commenting on his appointment, Colin says
“I am delighted and honoured to have been appointed as chair of NunaBio. As a business owner local to the North East I am very much looking forward to being involved in this company which has such an exciting future.”
NunaBio is a privately owned life sciences company based in the northeast of the UK.
Founded in 2021, our multi-patented technology can quickly produce large quantities of pure synthetic DNA using environmentally conscious processes.
NunaBio’ platform enables the synthesis of whole genes and DNA fragments of unprecedented length without the use of plasmids or primers, which are existing bottlenecks in the synthetic biology industry. Our technology has broad applications across multiple areas of life sciences, including gene therapy, T cell engineering, viral vector synthesis, hybridisation capture and targeted biomarker panels.
Our mission is to enable game changing technologies across the life sciences and biotech sectors by providing novel high-quality material at scale – we are not only making products, we are empowering the most cutting-edge technologies to make an impact on the world.